Targeted therapy before and after surgery for BRAF-mutant anaplastic thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of thyroid cancer called anaplastic (ATC) that has a BRAF V600E or V600K gene change.
- The cancer has not spread to other parts of your body (no distant metastases).
- Your airway is clear, or you have a tube or stent to keep it open, and you can swallow pills.
- You have not had any prior chemotherapy, immunotherapy, or radiation for this cancer.
- You are in good overall health (able to do daily activities) and your blood test results meet specific safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.